3[4-(3',4'-dichlorophenyl)piperazinyl]-1,2-epoxypropane | 335165-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3[4-(3',4'-dichlorophenyl)piperazinyl]-1,2-epoxypropane
• 英文别名: (+/-)-1-(3,4-Dichloro-phenyl)-4-oxiranylmethyl-piperazine；1-(3,4-Dichloro-phenyl)-4-oxiranylmethyl-piperazine；1-(3,4-dichlorophenyl)-4-(oxiran-2-ylmethyl)piperazine
• CAS: 335165-60-1
• 化学式: C₁₃H₁₆Cl₂N₂O
• 分子量: 287.189
• InChiKey: HSFLILGFYVAQJE-UHFFFAOYSA-N

物化性质

• 沸点：
  424.3±45.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  19
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-溴茶碱 、 3[4-(3',4'-dichlorophenyl)piperazinyl]-1,2-epoxypropane 在 吡啶 作用下， 以 丙醇 为溶剂， 反应 10.0h， 以90%的产率得到7-[4-(-3',4'-dichlorophenyl)-piperazin-1-yl-methylene]-1,3-dimethyl-6,7-dihydro-1,3-oxazolo[2,3-f]-purine-2,4(1H,3H)-dione
  参考文献：
  名称：

  靶向血清素 5-HT1A/5-HT2A/5-HT7 和多巴胺 D2 受体的 8-烷氧基-嘌呤-2,6-二酮和二氢[1,3]恶唑并[2,3-f]嘌呤二酮的新型芳基哌嗪基烷基衍生物

  摘要：

  为了获得潜在的抗抑郁药和/或抗精神病药，8-烷氧基-嘌呤-2,6-二酮（10-24）和二氢[1,3]恶唑并[2,3-f]的一系列新的长链芳基哌嗪衍生物合成嘌呤二酮 (30-34) 并测定其血清素 (5-HT1A、5-HT2A、5-HT6、5-HT7) 和多巴胺 (D2) 受体亲和力。该研究允许鉴定一些对 5-HT2A 位点具有中等亲和力的有效 5-HT1A/5-HT7/D2 配体。在计算研究中分析了来自两种化学类别（11 和 31）的代表性化合物在 5-HT1A 受体部位的结合模式。在体外功能研究中，选定的化合物 15 和 16 显示出对所评估受体的拮抗特性。8-甲氧基-7-{4-[4-(2-甲氧基苯基)-哌嗪-1-基]-丁基}-1,3-二甲基-嘌呤-2，

  DOI：

  10.1002/ardp.201500015
• 作为产物：
  描述：

  1-(3,4-二氯苯基)哌嗪 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 39.0h， 生成 3[4-(3',4'-dichlorophenyl)piperazinyl]-1,2-epoxypropane
  参考文献：
  名称：

  Synthesis and antidepressant activity of 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines

  摘要：

  The synthesis of 20 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines is described. Antidepressant activity was observed in mice using classical screening tests. Structure-activity relationships were studied and correlated with the nature of the aromatic substituent. Preliminary lipophilic and electronic properties of one lead compound (COR 3224) have been described.

  DOI：

  10.1016/0223-5234(92)90177-3

文献信息

• 9-(Piperazinylalkyl)carbazoles as Bax-modulators
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1094063A1

  公开（公告）日：2001-04-25

  The present invention is related to piperazine derivatives of carbazole notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of carbazole are efficient modulators, in particular inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel piperazine derivatives of carbazole as well as methods of their preparation.

  本发明涉及哌嗪衍生物的咔唑，特别用作药用活性化合物，以及含有这种哌嗪衍生物的咔唑的药物配方。所述的哌嗪衍生物的咔唑是有效的调节剂，特别是Bax功能和/或激活的抑制剂。本发明还涉及新型哌嗪衍生物的咔唑以及其制备方法。
• [EN] 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS<br/>[FR] 9- (PIPERAZINYLALKYL) CARBAZOLES UTILES EN TANT QUE MODULATEURS DE BAX
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2001029028A1

  公开（公告）日：2001-04-26

  The present invention is related to piperazine derivatives of carbazole of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of carbazole are efficient modulators, in particular efficient inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel piperazine derivatives of carbazole as well as methods of their preparation.

  本发明涉及式(I)的嘧啶二酰胺衍生物，特别是作为药物活性化合物的使用，以及含有这种嘧啶二酰胺衍生物的制药配方。所述嘧啶二酰胺衍生物是高效的调节剂，特别是高效的抑制剂，对Bax功能和/或激活具有作用。本发明还涉及新的嘧啶二酰胺衍生物以及其制备方法。
• 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS
  申请人：HALAZY Serge

  公开号：US20120040933A1

  公开（公告）日：2012-02-16

  piperazine compounds for use as pharmaceutically active compounds and in pharmaceutical formulations that are useful for the treatment of disorders associated with apoptosis, including neurodegenerative disorders, diseases associated with polyglutamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders, renal hypoxia, hepatitis and AIDS, where the piperazine compounds are represented by formula (I) and the terms R 0 , R 1 , R 2 , R 3 , k, l, m, n, and X are defined herein:

  使用哌嗪化合物作为药物活性化合物和制药配方，可用于治疗与凋亡相关的疾病，包括神经退行性疾病、多谷氨酸链相关疾病、癫痫、缺血、不育症、心血管疾病、肾脏缺氧、肝炎和艾滋病等。其中，哌嗪化合物由公式（I）表示，其中R0，R1，R2，R3，k，l，m，n和X的定义如下：
• 9-(piperazinylalkyl) carbazoles as bax-modulators
  申请人：Merck Serono SA

  公开号：US08053436B1

  公开（公告）日：2011-11-08

  The present invention is related to piperazine derivatives of carbazole of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of carbazole are efficient modulators, in particular efficient inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel piperazine derivatives of carbazole as well as methods of their preparation.

  本发明涉及公式(I)的咪唑衍生物的咔唑，特别是用作药物活性化合物的咪唑衍生物的咔唑，以及含有这种咪唑衍生物的咔唑的制药配方。所述的咪唑衍生物的咔唑是高效的调节因子，特别是高效的抑制剂，可用于Bax功能和/或激活。本发明还涉及新型咪唑衍生物的咔唑以及其制备方法。
• 9-(piperazinylalkyl) carbazoles as Bax-modulators
  申请人：Halazy Serge

  公开号：US08410110B2

  公开（公告）日：2013-04-02

  Piperazine compounds for use as pharmaceutically active compounds and in pharmaceutical formulations that are useful for the treatment of disorders associated with apoptosis, including neurodegenerative disorders, diseases associated with polyglutamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders, renal hypoxia, hepatitis and AIDS, where the piperazine compounds are represented by formula (I) and the terms R0, R1, R2, R3, k, l, m, n, and X are defined herein:

  Piperazine化合物可用作药物活性化合物和制药配方，对于与凋亡有关的疾病的治疗有用，包括神经退行性疾病、与多谷氨酸氨基酸序列相关的疾病、癫痫、缺血、不孕症、心血管疾病、肾脏缺氧、肝炎和艾滋病，其中Piperazine化合物由公式（I）表示，术语R0、R1、R2、R3、k、l、m、n和X在此定义：